SIGA on Nasdaq

SIGA TECHNOLOGIES INC

We are a commercial-stage pharmaceutical company.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Grace Therapeutics, Inc., Cytokinetics or Amylyx Pharmaceuticals, or pick any stock.

  • TickerSIGA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersNew York, New York1
  • Incorporated inDE2
  • Business address31 East 62Nd Street, New York, Ny 100652
  • Filer categoryAccelerated filer2

See how the biggest companies compare on our leaderboards

We are a commercial-stage pharmaceutical company. The Company sells its lead product, TPOXX® (“oral TPOXX®,” also known as "tecovirimat," "Tecovirimat-SIGA," or "TEPOXX (tecovirimat)" in certain international markets), to the U.S. Government and international governments (including government affiliated entities). In certain international markets, the Company may sell TPOXX® through a distributor. Additionally, the Company sells the intravenous formulation of TPOXX® ("IV TPOXX®") to the U.S. Government.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

25.1%Operating margin4
24.6%Net margin4
-31.8%Revenue growth, 20254
11.7%Return on equity4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product sales and supportive services brought in 93% of the revenue SIGA TECHNOLOGIES INC broke down this way in fiscal 2025.

  1. Product sales and supportive services$88.0M493%down 34% from 2024
  2. Research And Development$6.5M47%up 21% from 2024
Products and services by year
Products and services202320242025
Product sales and supportive services$130.7M$133.3M$88.0M
Research And Development$9.2M$5.4M$6.5M

Regions

United States brought in 88% of the revenue SIGA TECHNOLOGIES INC broke down this way in fiscal 2025.

  1. United States$88.8M488%down 23% from 2024
  2. CA [member]$5.8M46%up 689% from 2024
  3. Rest of the world$5.8M46%down 75% from 2024
Regions by year
Regions202320242025
United States$118.7M$115.7M$88.8M
CA [member]$0$737.7K$5.8M
Rest of the world$21.3M$23.0M$5.8M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue29¢$29.7M
  • Research and development20¢$20.0M
  • Selling, general and admin21¢$21.2M
  • Income tax7¢$7.1M
  • Profit23¢$23.3M

Out of $94.6M in revenue.4

Where each dollar of operating cash went, fiscal 2025

  • Dividends paid99¢$43.1M
  • Kept or used elsewhere1¢$354.9K

Out of $43.5M of cash from operations.4

Financial statements

Revenue56784$94.6M in 2025+254% since 2019
0$50.0M$100.0M$150.0M2019: $26.7M$26.7M20192020: $125.0M$125.0M2020+367%2021: $133.7M$133.7M2021+7%2022: $110.8M$110.8M2022−17%2023: $139.9M$139.9M2023+26%2024: $138.7M$138.7M2024−1%2025: $94.6M$94.6M2025−32%
Operating income56784$23.7M in 2025
-$25.0M0$25.0M$50.0M$75.0M$100.0M2019: -$2.3M-$2.3M20192020: $84.5M$84.5M20202021: $89.1M$89.1M2021+5%2022: $42.7M$42.7M2022−52%2023: $83.6M$83.6M2023+96%2024: $70.0M$70.0M2024−16%2025: $23.7M$23.7M2025−66%
Net income56784$23.3M in 2025
-$20.0M0$20.0M$40.0M$60.0M$80.0M2019: -$7.2M-$7.2M20192020: $56.3M$56.3M20202021: $69.5M$69.5M2021+23%2022: $33.9M$33.9M2022−51%2023: $68.1M$68.1M2023+101%2024: $59.2M$59.2M2024−13%2025: $23.3M$23.3M2025−61%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
RevenueFromContractWithCustomerExcludingAssessedTax$94.6M$138.7M$139.9M
CostOfGoodsAndServicesSold$29.7M$31.3M$17.8M
SellingGeneralAndAdministrativeExpense$21.2M$25.1M$22.0M
ResearchAndDevelopmentExpense$20.0M$12.3M$16.4M
CostsAndExpenses$70.9M$68.7M$56.3M
OperatingIncomeLoss$23.7M$70.0M$83.6M
NonoperatingIncomeExpense$6.7M$6.1M$4.2M
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest$30.4M$76.1M$87.8M
IncomeTaxExpenseBenefit-$7.1M-$16.9M-$19.7M
NetIncomeLoss$23.3M$59.2M$68.1M
EarningsPerShareBasic$0.33$0.83$0.95
EarningsPerShareDiluted$0.32$0.82$0.95
WeightedAverageNumberOfSharesOutstandingBasic71.5M shares71.3M shares71.4M shares
WeightedAverageNumberOfDilutedSharesOutstanding71.9M shares71.9M shares71.7M shares

Compare SIGA TECHNOLOGIES INC with another company

Leadership

Who has led SIGA TECHNOLOGIES INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Eric A. Rose Md.2007–2015
  2. Phillip Louis Gomez Iii.2016–2019
  3. Diem Nguyen2024–now

Chair

  1. Eric A. Rose Md.2016–2018

Chief financial officer

  1. Thomas N. Konatich2007–2008
  2. Ayelet Dugary2009
  3. Daniel J. Luckshire2011–now
2010201520202025
Board members and other officers (31)

Former names

  • SIGA PHARMACEUTICALS INCMar 10, 1997 to May 25, 20002

Timeline

  1. Jan 30, 2024New chief executive Diem Nguyen becomes CEO13
  2. Oct 24, 2016New chief executive Phillip Louis Gomez Iii. becomes CEO14
  3. Jul 30, 2007New chief executive Eric A. Rose Md. becomes CEO15

Filings

163 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 49 major events, 70 insider forms, 8 large holders, 16 other. The latest 20:

  1. Aug 6, 202610-Q EDGAR
  2. Aug 6, 20268-K EDGAR
  3. Jun 25, 2026S-8 EDGAR
  4. Jun 10, 20264 EDGAR
  5. Jun 10, 20264 EDGAR
  6. Jun 10, 20264 EDGAR
  7. Jun 10, 20264 EDGAR
  8. Jun 10, 20264 EDGAR
  9. Jun 10, 20264 EDGAR
  10. Jun 10, 20264 EDGAR
  11. Jun 10, 20268-K EDGAR
  12. May 8, 2026DEFA14A EDGAR
  13. May 7, 202610-Q EDGAR
  14. May 7, 20268-K EDGAR
  15. Apr 28, 2026ARS EDGAR
  16. Apr 28, 2026DEFA14A EDGAR
  17. Apr 28, 2026DEF 14A EDGAR
  18. Mar 26, 20264 EDGAR
  19. Mar 26, 20268-K EDGAR
  20. Mar 17, 20264 EDGAR

The 163 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 9, 2021Antal JamesDirectorSale30,000$7.82$234.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.4,186,282$15.2M0.0%+692,089
Dimensional Fund Advisors LP2,719,568$9.9M0.0%+16,844
AltraVue Capital, LLC2,327,144$8.5M0.6%−104,880
Vanguard Capital Management LLC1,712,701$6.2M0.0%−1,679
American Century Companies Inc1,506,065$5.5M0.0%+188,281
Arrowstreet Capital, Limited Partnership1,474,817$5.4M0.0%−51,143
Geode Capital Management, LLC1,417,092$5.2M0.0%+101,547
First Wilshire Securities Management Inc1,339,883$4.9M1.0%+449,385
Aqr Capital Management LLC1,245,992$4.5M0.0%+26,315
State Street Corp1,133,989$4.1M0.0%+122,051
Hotchkis & Wiley Capital Management LLC914,047$3.3M0.0%+87,000
Qube Research & Technologies Ltd740,910$2.7M0.0%+325,806
New York State Common Retirement Fund590,761$2.2M0.0%No change
Millennium Management LLC579,599$2.1M0.0%+113,275
Jacobs Levy Equity Management, Inc566,863$2.1M0.0%+275,017
Uniplan Investment Counsel, Inc.560,353$2.0M0.2%+188,940
Citadel Advisors LLC551,246$2.0M0.0%−153,891
Royce & Associates LP551,010$2.0M0.0%−116,636
Vanguard Portfolio Management LLC549,697$2.0M0.0%−37,277
Legato Capital Management LLC512,039$1.9M0.2%No change
Bank Of America Corp /de/427,275$1.6M0.0%−57,397
Renaissance Technologies LLC425,800$1.5M0.0%−49,213
Morgan Stanley421,009$1.5M0.0%+157,674
Denali Advisors LLC414,436$1.5M0.2%−22,451
Goldman Sachs Group Inc393,007$1.4M0.0%−231,896

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53